BD (Becton, Dickinson and Company), a global medical technology company, today announced a strategic partnership with Healthians, a premier diagnostics service provider, to advance cervical cancer screening by offering an innovative option for women to self-collect a sample in the privacy of their own homes.

For women , social stigma around getting a pelvic examination, lack of time, embarrassment, fear, and inconvenience are among the key barriers to screening. At-home self-collection can help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening. The objective of this partnership is to improve the access to cervical cancer screening in India, where less than 2 per cent women are currently being screened.

Deepak Sahni, Founder & Chairman, Healthians, said, “At Healthians, we envision a world where we're not just fighting diseases but preventing them. With our HPV self-testing initiative, we're providing a path to early detection of cervical cancer, levelling the playing field in a battle where time is of essence. With our strong foothold in the market as a direct-to-consumer player since our inception in 2014, we believe we are in the best position to bring about substantial awareness on cervical cancer risk screening, offering women a convenient platform to get tested from the privacy of their homes. We stand together in this journey with BD, for a future where the screening of 'cervical cancer' becomes a routine affair.”

In 2020, the World Health Organization (WHO) launched its Global Strategy to Accelerate the Elimination of Cervical Cancer, recognizing the potential to virtually eliminate cervical cancer as a public health threat. The strategy established clear targets to achieve by 2030 for HPV vaccination coverage (>90 per cent ), screening coverage (>70 per cent ) and access to treatment (>90 per cent ).

Commenting on the launch, Atul Grover, Managing Director, BD India/South Asia, said, “Cervical cancer ranks as the second most common cancer; however, it is one of the most preventable and treatable types of cancer if detected early. The key to prevention and patient safety lies in timely screening. Our at-home self-collection, in partnership with Healthians aims to provide women exactly that: increased access to HPV testing by enabling them to collect a sample in the privacy of their homes. This is aligned with BD’s purpose of advancing the world of health by expanding access to healthcare for superior patient outcomes.”

As per the IARC Information Center on HPV and Cancer, current estimates indicate that every year, 123907 women are diagnosed with cervical cancer and 77,348 die from the disease. Cervical cancer ranks as the 2nd most frequent cancer among women in India and the 2nd most frequent cancer among women between 15 and 44 years of age. Almost all cervical cancer cases (more than 95 per cent ) are caused by a persistent genital high-risk human papillomavirus (HPV) infection.


About Healthians

It is a leading health test at-home service, offering a wide range of health tests across 250+ cities . It has a network of state-of-the-art, fully automated laboratories and a large team of highly skilled phlebotomists who specialize in sample collection from homes. Technological innovation has been the foundation of the brand in the industry. The company has completely turned a customer's diagnostic experience on its head, by focusing on delivering the best diagnostic service experience fulfilled through high-end technology and stringent quality parameters.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care.

About BD Onclarity HPV Assay

The BD Onclarity HPV Assay detects and identifies 14 high-risk human papillomavirus (HPV) types in a single analysis and provides extended genotyping information from specimens collected for cervical cancer screening purposes. The assay is for use in accordance with clinical guidelines and within the scope of local regulatory authorizations as part of a comprehensive approach to cervical cancer screening. The BD Onclarity HPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in the co-testing paradigm, and in primary HPV screening. The assay has also met international criteria for primary HPV screening. BD Onclarity HPV Assay has FDA approval for use in vaccinated women.